Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05886218 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 4 more changesShow less
    • Results posted: Oct 9, 2026
    • Trial completed
    • Final enrollment: 183 participants (planned 215)
    • Trial arms changed: 0 → 2
  2. Results first posted: Oct 9, 2026 Show 11 more changesShow less
    • Start date: Feb 8, 2023 to Jan 8, 2024
    • Primary endpoint revised
    • Trial status: Recruiting to Completed
    • Enrollment target: estimated 215 to confirmed 183
    • Primary completion date changed from estimate of Jul 2025 to Jun 5, 2025
    • Study completion date changed from estimate of Jul 2025 to Aug 27, 2025
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: 7 to 6
    • Study description expanded, about 90 words
    • Site details revised
    • Study arms: 0 to 2
  3. Primary completion date: Apr 2025 to Jul 2025v5
  4. Primary completion date: Feb 2025 to Apr 2025v4
  5. Primary completion date: Feb 2024 to Feb 2025
    • Study completion date: Jul 2024 to Jul 2025
    v3
  6. Secondary endpoints: details revised at 5 of 7 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.
Trial Details
NCT Number NCT05886218
Lead Sponsor University of California, Davis
Conditions
(from sponsor)		 Sugammadex
Enrollment 183 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov